Genexine (095700) Fundamentals 2026 — Revenue Analysis | SniperIQ
Genexine (095700) is a KR-listed Healthcare company in Biotechnology with a market capitalization of ₩106.4B, trading at ₩2340.00 on the KOE. This SniperIQ fundamentals page covers Genexine's valuation, profitability (net margin -439.8%), revenue (₩4.6B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Genexine's market cap?
Genexine (095700) has a market capitalization of approximately ₩106.4B, trading at ₩2340.00 on the KOE. Market cap moves with the live share price.
What is Genexine's P/E ratio?
Genexine's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 0.5x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Genexine?
Genexine runs a net profit margin of -439.8%, a gross margin of -41.8%, and an operating margin of -780.3%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Genexine generate?
Genexine reported revenue of ₩4.6B for fiscal year 2025, with net income of -₩27.0B and earnings per share (EPS) of -594.1. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Genexine pay a dividend?
Genexine does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Genexine financially healthy?
Genexine carries a debt-to-equity ratio of 0.45x and a current ratio of 0.30x, with a market beta of 0.39. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Genexine a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Genexine (095700) the key facts are: market cap ₩106.4B, revenue ₩4.6B, 52-week range 2140-7490. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Genexine's full fundamentals live
Get Genexine's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.